Plant Name: Corydalis yanhusuo
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA2A; ADORA1; HTR7; HTR5A; ADRA1A; DRD3; DRD1; DRD2; ADORA3; HTR2B; HTR2A; HTR1A; HTR6; | |
| GAA; BCHE; ACHE; | |
| TDP1; ADK; HPGD; ALOX15; SENP6; SENP8; SENP7; | |
| CASP3; | |
| HIF1A; STAT6; | |
| CREBBP; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| HTT; LMNA; RAD52; SIGMAR1; F3; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cysteine protease | CASP3 | Caspase-3 | P42574 | CHEMBL2334 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | SENP7 | Sentrin-specific protease 7 | Q9BQF6 | CHEMBL1741213 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | SENP6 | Sentrin-specific protease 6 | Q9GZR1 | CHEMBL1741215 |
| Enzyme_unclassified | SENP8 | Sentrin-specific protease 8 | Q96LD8 | CHEMBL1741207 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.105E-11 | 2.406E-08 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.105E-11 | 2.406E-08 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.966E-11 | 3.374E-08 | HTR1A, HTR2A, HTR2B, HTR5A, HTR7 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 4.836E-11 | 7.020E-08 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, F3, HPGD, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SENP7, SIGMAR1, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 2.758E-10 | 2.502E-07 | ADORA1, ADORA2A, ADRA1A, DRD1, HTR1A, HTR2A, HTR2B, HTR7 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.182E-10 | 2.669E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 3.219E-10 | 2.669E-07 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1, SLC28A1, SLC28A2, SLC28A3, TSHR |
| MF | Unclassified; | GO:0004872; receptor activity | 1.583E-09 | 9.851E-07 | ADORA1, ADORA2A, ADORA3, ADRA1A, DRD1, DRD2, DRD3, F3, HPGD, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SENP7, SIGMAR1, TSHR |
| BP | Unclassified; | GO:0042310; vasoconstriction | 4.907E-09 | 2.671E-06 | ADRA1A, HTR1A, HTR2A, HTR2B, HTR7 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 1.500E-08 | 7.257E-06 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.658E-08 | 7.419E-06 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B, HTT |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 4.104E-08 | 1.655E-05 | HTR1A, HTR5A, HTR7 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.005E-07 | 3.647E-05 | DRD1, DRD2, DRD3, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 3.071E-07 | 1.013E-04 | ADORA2A, DRD1, DRD2, DRD3 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.574E-07 | 1.112E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 5.710E-07 | 1.615E-04 | DRD1, DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 6.411E-07 | 1.767E-04 | ADORA1, DRD1, DRD2, HTR2A |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.177E-07 | 2.145E-04 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTT |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 8.552E-07 | 2.217E-04 | ADORA1, ADORA2A, ADORA3 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 9.911E-07 | 2.481E-04 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTR5A, HTR6, HTT, MAPT, SMN1, SMN2 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 1.675E-06 | 3.921E-04 | DRD2, DRD3, HTR2B |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 1.736E-06 | 3.978E-04 | ADORA2A, BCHE, CASP3, DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.229E-06 | 4.854E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.229E-06 | 4.854E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 2.894E-06 | 5.984E-04 | ADORA2A, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 2.894E-06 | 5.984E-04 | DRD1, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.968E-06 | 5.984E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 3.677E-06 | 6.902E-04 | ADORA1, DRD2, HTR2A |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 3.857E-06 | 7.178E-04 | DRD1, DRD2, DRD3, HIF1A |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 4.841E-06 | 8.570E-04 | SLC28A2, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 4.841E-06 | 8.570E-04 | ACHE, BCHE |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 4.841E-06 | 8.570E-04 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 4.841E-06 | 8.570E-04 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.276E-06 | 9.118E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 5.639E-06 | 9.446E-04 | ADORA1, ADORA2A, MAPT |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.019E-05 | 1.541E-03 | ADORA2A, DRD1, DRD2, DRD3, HIF1A, HTT |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.450E-05 | 1.986E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.450E-05 | 1.986E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 1.450E-05 | 1.986E-03 | DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.450E-05 | 1.986E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.450E-05 | 1.986E-03 | ADORA1, ADORA2A |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.764E-05 | 2.314E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 2.013E-05 | 2.573E-03 | ADRA1A, HTR2A, HTR2B |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.206E-05 | 2.745E-03 | ADORA1, CASP3, CREBBP, DRD2, HIF1A, LMNA |
| BP | GO:0023052; signaling | GO:0046883; regulation of hormone secretion | 2.404E-05 | 2.909E-03 | ADORA1, ADORA2A, DRD2, HIF1A, HTR1A, HTR2A |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.734E-05 | 3.167E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.896E-05 | 3.285E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 3.238E-05 | 3.597E-03 | DRD2, DRD3, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.676E-05 | 4.826E-03 | ACHE, ADORA3, ALOX15, CASP3, DRD2 |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 4.676E-05 | 4.826E-03 | ADORA2A, DRD1, DRD2, DRD3, GAA |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 4.820E-05 | 4.855E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 4.820E-05 | 4.855E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0042321; negative regulation of circadian sleep/wake cycle, sleep | 4.820E-05 | 4.855E-03 | ADORA1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 4.820E-05 | 4.855E-03 | HTR2A, HTR2B |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.860E-05 | 5.646E-03 | CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 6.605E-05 | 6.146E-03 | ADORA1, DRD1, DRD2, HTR2A |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 7.220E-05 | 6.497E-03 | ALOX15, HPGD |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.369E-05 | 6.603E-03 | ADRA1A, ALOX15, DRD2, HTR2A, HTR2B |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 7.574E-05 | 6.704E-03 | ADORA3, DRD1, TSHR |
| BP | GO:0007610; behavior | GO:0007613; memory | 8.643E-05 | 7.380E-03 | DRD1, DRD2, HTR2A, MAPT |
| MF | GO:0005488; binding | GO:0031072; heat shock protein binding | 8.643E-05 | 7.380E-03 | ADORA1, HIF1A, HTT, MAPT |
| BP | GO:0023052; signaling | GO:0032222; regulation of synaptic transmission, cholinergic | 1.009E-04 | 8.325E-03 | ACHE, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0016926; protein desumoylation | 1.009E-04 | 8.325E-03 | SENP6, SENP8 |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 1.110E-04 | 9.022E-03 | ADORA1, DRD2, DRD3 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.201E-04 | 9.653E-03 | DRD2, DRD3, F3, HIF1A, HPGD, HTR1A, HTR2A, HTR2B, TSHR |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.230E-04 | 9.846E-03 | DRD2, HTR5A, SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.765E-16 | 3.577E-14 | HTR1A; HTR2B; HTR2A; HTR5A; ADRA1A; TSHR; HTR6; HTR7; ADORA2A; ADORA3; ADORA1; DRD1; DRD2; DRD3 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.306E-14 | 1.570E-12 | HTR6; HTR7; CYP2D6; CASP3; ALOX15; HTR1A; HTR2B; HTR2A; HTR5A; CYP2C19 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 4.082E-09 | 1.293E-07 | HTR6; HTR7; ADORA2A; HTR2B; HTR2A; DRD1; HTR5A; ADRA1A |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.978E-09 | 2.132E-07 | CREBBP; HTR6; ADORA2A; ADORA1; HTR1A; DRD1; DRD2; TSHR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.230E-07 | 8.036E-06 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.446E-05 | 2.290E-04 | CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.788E-05 | 5.140E-04 | HTR2B; HTR2A; DRD1; DRD2 |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 2.424E-04 | 2.879E-03 | ADORA2A; CASP3; DRD1; DRD2 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.184E-04 | 5.472E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.283E-04 | 6.919E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.680E-03 | 2.314E-02 | DRD1; DRD2; DRD3 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.798E-03 | 3.007E-02 | CREBBP; CASP3; STAT6 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.524E-03 | 3.748E-02 | ADORA3; ADORA1; ADRA1A |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 6.690E-03 | 3.864E-02 | ADORA2A; DRD1; DRD2 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.980E-03 | 3.639E-02 | DRD1; DRD2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.460E-03 | 3.864E-02 | ADORA1; TSHR |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 8.224E-03 | 4.016E-02 | CREBBP; CASP3; HTT |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 7.868E-03 | 4.016E-02 | ALOX15; CYP2C19 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.877E-03 | 4.016E-02 | CREBBP; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.915E-03 | 3.864E-02 | CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.619E-03 | 4.016E-02 | CYP1A2; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.070E-02 | 4.623E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; CYP2D6 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT; HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3 |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; HTR2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1A; HTR2B; HTR2A; CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; DRD2; HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; HTR1A; HTR1A; DRD3; DRD1; DRD2; DRD2; DRD2; DRD2; HTR2A; HTR2A; HTR6 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| NA: NA | Episode | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA2A; ADORA1; ADRA1A; DRD2; ACHE; ADORA3; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HTR1A; HTR1A; ADRA1A; DRD2 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| NA: NA | Social phobia | NA | HTR1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; HTR1A; DRD2; ACHE; ACHE; ACHE; MAPT; HTR6; HTR6; HTR6 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; DRD2 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; ADRA1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A; HTR2B; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A; HTR2A |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; ACHE; ADORA3; CASP3 |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; HTR1A; ADRA1A; DRD1; ACHE; MAPT; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3; DRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; HTR1A; DRD1; DRD2; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; HTR1A; ADK; ADRA1A; DRD1; DRD2; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1A; CYP3A4; DRD2; ACHE; HTR2A; HTR6; HTR6 |
| NA: NA | Cervical dystonia | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; ADORA3 |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| NA: NA | Addiction | NA | HTR2A |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; DRD2 |
| NA: NA | Anxiety disorders | NA | HTR1A |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; HTR1A; ADRA1A; DRD1; DRD2; DRD2 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| NA: NA | False perceptions | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| NA: NA | Vomiting | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1; DRD2 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; ADRA1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1 |
| NA: NA | Itching | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1A; DRD3; DRD1; DRD2 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3 |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR1A; DRD1; HTR2A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| NA: NA | Hyperaemia | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; ADRA1A; DRD3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |